Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer

British Journal of Cancer

Volumn 108, Issue 3, 2013, Pages 519-526

  Lorenzen, S ^a   Pauligk, C ^b   Homann, N ^c   Schmalenberg, H ^d   Jager E ^b   Al Batran, S E ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b KRANKENHAUS NORDWEST   (Germany)

^c Klinikum Wolfsburg   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGOGASTRIC CANCER; ESOPHAGUS CANCER; FATIGUE; FEASIBILITY STUDY; FEMALE; GERIATRIC PATIENT; HOSPITALIZATION; HUMAN; INFECTION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SENSORY NEUROPATHY; STOMACH CANCER; SURGICAL MORTALITY; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESOPHAGEAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; ORGANOPLATINUM COMPOUNDS; PERIOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 84875231301     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.588     Document Type: Article

References (29)

1. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA (2006) Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 24: 3953-3958.
2. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A, Jäger E (2008a) Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 19: 1882-1887.
3. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E. Arbeitsgemeinschaft Internistische Onkologie (2008b) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26: 1435-1442.
4. Al-Batran SE, Pauligk C, Homann N, Hartmann JT, Moehler M, Probst S, Rethwisch V, Stoehlmacher-Williams J, Prasnikar N, Hollerbach S, Bokemeyer C, Mahlberg R, Hofheinz RD, Luley K, Kullmann F, Jager E (2012) The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65\+). Eur J Cancer.
5. Biffi R, Fazio N, Luca F, Chiappa A, Andreoni B, Zampino MG, Roth A, Schuller JC, Fiori G, Orsi F, Bonomo G, Crosta C, Huber O (2010) Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locallyadvanced gastric cancer. World J Gastroenterol 16: 868-874.
6. Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM (2006) Selecting a specific pre-or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6: 931-939.
7. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathé G (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82: 1046-1050.
8. Cronin-Fenton DP, Sharp L, Carsin AE, Comber H (2007) Patterns of care and effects on mortality for cancers of the oesophagus and gastric cardia: a population-based study. Eur J Cancer 43(3): 565-575.
9. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. MAGIC (2006) Trial Participants Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20.
10. El-Serag HB (2002) The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am 31: 421-440.
11. Fields RC, Busam KJ, Chou JF, Panageas KS, Pulitzer MP, Allen PJ, Kraus DH, Brady MS, Coit DG (2012) Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma. Cancer 118(13): 3311-3320.
12. Homann N, Pauligk C, Luley K, Werner Kraus T, Bruch HP, Atmaca A, Noack F, Altmannsberger HM, Jäger E, Al-Batran SE (2012) Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer 130: 1706-1713.
13. Hutchins LF, Unger JM, Crowley JJ, Coltman Jr CA, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancertreatment trials. N Engl J Med 341: 2061-2067.
14. Japanese Gastric Cancer A (1998) Japanese classification of gastric carcinoma-2nd english edition. Gastric Cancer 1: 10-24.
15. Jatoi A, Foster NR, Egner JR, Burch PA, Stella PJ, Rubin J, Dakhil SR, Sargent DJ, Murphy BR, Alberts SR (2010) Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. Int J Oncol 36: 601-606.
16. Kelley ST, Coppola D, Karl RC (2004) Neoadjuvant chemoradiotherapy is not associated with a higher complication rate vs. surgery alone in patients undergoing esophagectomy. J Gastrointest Surg 8: 227-231(discussion 231-232).
17. Koppert LB, Lemmens VE, Coebergh JW, Steyerberg EW, Wijnhoven BP, Tilanus HW, Janssen-Heijnen ML (2012) Impact of age and co-morbidity on surgical resection rate and survival in patients with oesophageal and gastric cancer. Br J Surg 99(12): 1693-1700.
18. Lin FC, Durkin AE, Ferguson MK (2004) Induction therapy does not increase surgical morbidity after esophagectomy for cancer. Ann Thorac Surg 78: 1783-1789.
19. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Röthling N, Peschel C, Lordick F et al. (2007) Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 18: 1673-1679.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214.
21. Rice DC, Correa AM, Vaporciyan AA, Sodhi N, Smythe WR, Swisher SG, Walsh GL, Putnam Jr JB, Komaki R, Ajani JA, Roth JA (2005) Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg 79: 391-397(discussionn 391-397).
22. Ruol A, Portale G, Castoro C, Merigliano S, Cagol M, Cavallin F, Chiarion Sileni V, Corti L, Rampado S, Costantini M, Ancona E (2007) Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer. Ann Surg Oncol 14: 3243-3250.
23. Sabel MS, Smith JL, Nava HR, Mollen K, Douglass HO, Gibbs JF (2002) Esophageal resection for carcinoma in patients older than 70 years. Ann Surg Oncol 9(2): 210-214.
24. Sym SJ, Chang HM, Ryu MH, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK (2010) Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. Ann Surg Oncol 17: 1024-1032.
25. Thuss-Patience PC, Hofheinz RD, Arnold D, Florschutz A, Daum S, Kretzschmar A, Mantovani-Loffler L, Bichev D, Breithaupt K, Kneba M, Schumacher G, Glanemann M, Schlattmann P, Reichardt P, Gahn B (2012) Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol 23(11): 2827-2834.
26. Trumper M, Ross PJ, Cunningham D, Norman AR, Hawkins R, Seymour M, Harper P, Iveson T, Nicolson M, Hickish T (2006) Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. Eur J Cancer 42: 827-834.
27. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA. V325 Study Group (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991-4997.
28. van de Velde CJ, Peeters KC (2003) The gastric cancer treatment controversy. J Clin Oncol 21(12): 2234-2236.
29. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29(13): 1715-1721.